- $58.35bn
- $57.34bn
- $2.31bn
Brief: Exelixis And Natera To Collaborate On Stellar-316, A Phase 3 Pivotal Trial Of Zanzalintinib
Brief: Natera Files For Offering Of Up To 1.95 Mln Shares Of Common Stock By Selling Stockholders
Brief: Natera Acquires Foresight Diagnostics
Genetic testing firm Natera beats Q3 revenue estimates, raises 2025 revenue forecast
Brief: Natera Q3 Revenue USD 592.2 Million Vs. IBES Estimate USD 512.5 Million
U.S. RESEARCH ROUNDUP-Blackstone, Ford, Intel
Brief: Natera Inc Says IMvigor011 Trial Achieves 41% Improvement In Overall Survival
Brief: Natera Says To Present 14 Studies At ESMO, Including Imvigor011 Oral Presentation
NeoGenomics rises after winning patent infringement lawsuit against Natera
Brief: Natera Provides Update on Patent Litigation with NeoGenomics
NeoGenomics rises after winning patent infringement lawsuit against Natera
Brief: Signatera Test Selected for NRG-Sponsored Phase III ARCHER Trial in Bladder Cancer
Brief: Imvigor011 Bladder Cancer Trial Achieves Positive Results, With Signatera™ Strongly Predicting Adjuvant Immunotherapy Benefit
U.S. RESEARCH ROUNDUP-Bd, Caci International, Caterpillar
Natera Inc reports results for the quarter ended June 30 - Earnings Summary
Brief: Natera Q2 Net Income USD -100.9 Million
US judge rebukes law firm Quinn Emanuel, awards $3 million sanction in Guardant case
Brief: Natera Inc - Signatera Assay Now Covered By Medicare
Natera Inc reports results for the quarter ended March 31 - Earnings Summary